| All n = 165 | 1995-2000 n = 48 | 2004-2009 n = 117 | Pvalue |
---|---|---|---|---|
Gender (female) | 47 (29%) | 10 (21%) | 37 (32%) | 0.163 |
Age, years | 38 (10) | 38 (9) | 38 (11) | 0.810 |
SIMD†, quntile |  |  |  | 0.040 |
   1 (most deprived) | 24 (15%) | 10 (21%) | 14 (13%) |  |
   2 | 22 (14%) | 8 (17%) | 13 (13%) |  |
   3 | 38 (24%) | 13 (27%) | 25 (22%) |  |
   4 | 38 (24%) | 9 (19%) | 29 (26%) |  |
   5 (least deprived) | 38 (24%) | 8 (17%) | 30 (27%) |  |
Origin | Â | Â | Â | 0.226 |
   UK | 108 (66%) | 36 (75%) | 72 (62%) |  |
   sub-Saharan Africa | 39 (24%) | 9 (19%) | 30 (26%) |  |
   Other | 18 (11%) | 3 (6%) | 15 (13%) |  |
Area of presumed acquisition | Â | Â | Â | 0.026 |
   UK | 78 (47%) | 30 (63%) | 48 (41%) |  |
   Europe | 10 (6%) | 2 (4%) | 8 (7%) |  |
   sub-Saharan Africa | 58 (35%) | 14 (29%) | 44 (38%) |  |
   Asia/SE Asia | 19 (12%) | 2 (4%) | 17 (15%) |  |
   UK origin acquired in high-risk area. | 26 (16%) | 6 (12%) | 20 (17%) |  |
Previous (negative) HIV test | 51 (31%) | 13 (27%) | 38 (33%) | 0.469 |
   Months since last HIV test (if occurred) | 41 (42) | 29 (20) | 45 (47) | 0.090 |
Clinical staging at first presentation (WHO) | Â | Â | Â | 0.010 |
   Primary HIV infection | 3 (2%) | 0 (0%) | 3 (3%) |  |
   Stage 1 | 102 (62%) | 23 (48%) | 79 (68%) |  |
   Stage 2 | 11 (7%) | 5 (10%) | 6 (5%) |  |
   Stage 3 | 24 (15%) | 9 (18%) | 15 (13%) |  |
   Stage 4 | 25 (15%) | 11 (23%) | 14 (12%) |  |
Clinical staging at diagnosis (WHO) | Â | Â | Â | 0.002 |
   Primary infection | 2 (1%) | 0 (0%) | 2 (2%) |  |
   Stage 1 | 84 (51%) | 14 (30%) | 70 (60%) |  |
   Stage 2 | 12 (7%) | 6 (13%) | 6 (5%) |  |
   Stage 3 | 29 (18%) | 14 (29%) | 15 (13%) |  |
   Stage 4 | 38 (23%) | 14 (29%) | 24 (21%) |  |
Cd4 count at diagnosis (cells/mm3) | Â | Â | Â | 0.517 |
   < 200 | 66 (40%) | 21 (44%) | 45 (39%) |  |
   200-350 | 28 (17%) | 8 (17%) | 20 (17%) |  |
   > 350 | 71 (43%) | 19 (40%) | 52 (44%) |  |